Plain-English translation of NCT07609719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing ocrelizumab, a multiple sclerosis medication, given as an injection under the skin instead of through an IV. The study is for people with relapsing or primary progressive multiple sclerosis who are switching from another similar anti-CD20 therapy. Researchers want to see how well the medication works, how safe it is, and whether people prefer this new injection method.
Currently, some people receive this medication through an IV infusion at a clinic, which can be inconvenient or uncomfortable. This study is exploring whether giving the medication as a subcutaneous injection could make treatment easier for patients while maintaining the same benefits.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive two injections of the medication under your skin—one at the start of the study and one 6 months later. The study will include visits where doctors check your health, perform MRI brain scans to monitor your disease, and ask about how you're doing on the new medication. The study will last at least 6 months, and researchers will track how well the medication works, how safe it is, and whether you prefer this injection method over your previous treatment.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States